Guidance

MenACWY risk groups: patient group direction template

Patient group direction (PGD) template to support the provision of MenACWY vaccine to individuals with underlying medical conditions.

• From: UK Health Security Agency
• Published: 1 March 2017
• Last updated: 2 February 2023 — See all updates

Applies to England

Documents

MenACWY risk groups: PGD template

Ref: UKHSA gateway number GOV-14014

MS Word Document, 158 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the provision of additional meningococcal group A, C, W and Y (MenACWY) conjugate vaccine to individuals with underlying medical conditions.

MenACWY at risk groups PGD version 4.00 is valid from 28 February 2023 to 28 February 2025.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 1 March 2017
Last updated 2 February 2023 + show all updates

1. 2 February 2023

   Added version 04.00, see page 2 for changes.

2. 15 February 2021

   Added updated PGD: v3.00.

3. 15 February 2019

   Added version V04.00 - routine review of PGD prior to expiry and removal of black triangle status for Nimenrix.

4. 1 March 2017

   First published.